Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8548253 | 0.84 | MTNR1A (0.51) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6081151 | 0.77 | CA1 (0.43) | CA1CA2CA12CA7CA14 | |
| SCHEMBL9505624 | 0.73 | CA1 (0.63) | CA1CA2CA12CA7CA14 | |
| SCHEMBL30595323 | 0.73 | MTNR1A (0.77) | CA1CA2CA12CA7CA14 | |
| SCHEMBL1029693 | 0.73 | MTNR1A (0.77) | CA1CA2CA12CA7CA14 | |
| SCHEMBL23230039 | 0.73 | MTNR1A (0.53) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6075588 | 0.73 | MTNR1A (0.72) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6076582 | 0.73 | CA1 (0.41) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6076018 | 0.73 | CA1 (0.41) | CA1CA2CA12CA7CA14 | |
| SCHEMBL9092783 | 0.71 | MTNR1A (0.47) | CA1CA2CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0608568-B1 | Aminocycloalkanobenzodioxoles as beta-3 selective adrenergic agents | AMERICAN CYANAMID CO (US) | 1998-03-11 | — | — | EP | disclosed |
| US-5594027-A | TREATMENT OF DIABETES, HYPERGLYCEMIA AND OBESITY | AMERICAN CYANAMID COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5510376-A | TREATING DIABETES, HYPERGLYCEMIA, OBESITY | AMERICAN CYANAMID COMPANY (US) | 1996-04-23 | — | — | US | disclosed |
| EP-0608568-A1 | Aminocycloalkanobenzodioxoles as beta-3 selective adrenergic agents | AMERICAN CYANAMID COMPANY (US) | 1994-08-03 | — | — | EP | disclosed |